Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Proof-of-concept publication
10-11-2017
SHARING OPTIONS:

NEWARK, Calif.—CymaBay Therapeutics Inc.’s proof-of-concept study of seladelpar has been published in Lancet Gastroenterology and Hepatology, the company announced recently. Seladelpar is a potent, selective PPARδ agonist being advanced for the treatment of primary biliary cholangitis, an autoimmune liver disease. Dr. Pol Boudes, CymaBay’s chief medical officer, said the study demonstrated seladelpar’s ability to reverse cholestasis and decrease bile acid synthesis and inflammation.
 
“While we stopped this study because of an alanine aminotransferase (ALT) safety signal, we have recently announced the interim results of our ongoing low dose Phase 2 study in PBC which indicated that seladelpar retains its anticholestatic activity at lower doses (5 mg and 10 mg) while also decreasing transaminase levels. Based on these interim results we are further expanding the ongoing low dose Phase 2 study, and starting to plan our Phase 3 program,” Boudes said.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.